Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts

Summary

Jefferies has lowered expectations for Daiichi Sankyo as its key drugs Enhertu and Datroway approach peak revenue while competitors intensify competition in the antibody-drug conjugate market, with the company's pipeline lagging behind rivals.